Literature DB >> 15868380

A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer.

Heather Wakelee1, George A Fisher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15868380     DOI： 10.1007/s10637-005-6732-1

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  6 in total

1.  Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.

Authors:  Maria L Delioukina; Diane Prager; Mandy Parson; J Randolph Hecht; Peter Rosen; Lee S Rosen
Journal:  Cancer       Date:  2002-04-15       Impact factor: 6.860

2.  Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

Authors:  P Rougier; R Bugat; J Y Douillard; S Culine; E Suc; P Brunet; Y Becouarn; M Ychou; M Marty; J M Extra; J Bonneterre; A Adenis; J F Seitz; G Ganem; M Namer; T Conroy; S Negrier; Y Merrouche; F Burki; M Mousseau; P Herait; M Mahjoubi
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

3.  Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

Authors:  M L Rothenberg; J R Eckardt; J G Kuhn; H A Burris; J Nelson; S G Hilsenbeck; G I Rodriguez; A M Thurman; L S Smith; S G Eckhardt; G R Weiss; G L Elfring; D A Rinaldi; L J Schaaf; D D Von Hoff
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544

4.  The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)- ethylphosphorothioic acid (WR 2721).

Authors:  J L Millar; T J McElwain; R D Clutterbuck; E A Wist
Journal:  Am J Clin Oncol       Date:  1982-06       Impact factor: 2.339

5.  Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.

Authors:  M de Forni; R Bugat; G G Chabot; S Culine; J M Extra; A Gouyette; I Madelaine; M E Marty; A Mathieu-Boué
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

6.  Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.

Authors:  G Kemp; P Rose; J Lurain; M Berman; A Manetta; B Roullet; H Homesley; D Belpomme; J Glick
Journal:  J Clin Oncol       Date:  1996-07       Impact factor: 44.544
  6 in total
  2 in total

Review 1.  Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

Authors:  Umang Swami; Sanjay Goel; Sridhar Mani
Journal:  Curr Drug Targets       Date:  2013-06       Impact factor: 3.465

2.  The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018).

Authors:  Wing Lam; Zaoli Jiang; Fulan Guan; Rong Hu; Shwu-Huey Liu; Edward Chu; Yung-Chi Cheng
Journal:  BMC Complement Altern Med       Date:  2014-12-15       Impact factor: 3.659
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.